Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Thomas Bachelot, A Wroński, Tamar Peretz‐Yablonski et al.|Annals of Oncology|2019Cited by 117
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationDavid Miles, Hamdy Abdel Azeem, Eva Ciruelos et al.|Annals of Oncology|2021Cited by 92